Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 4:15:23-28.
doi: 10.2147/HIV.S395969. eCollection 2023.

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection

Biagio Pinchera  1 , Emanuela Zappulo  1 , Antonio Riccardo Buonomo  1 , Maria Rosaria Cotugno  1 , Giovanni Di Filippo  1 , Francesco Borrelli  1 , Simona Mercinelli  1 , Riccardo Villari  1 , Ivan Gentile  1
Affiliations

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection

Biagio Pinchera et al. HIV AIDS (Auckl). .

Abstract

Background: HCV-related liver disease is an important cause of morbidity and mortality in patients with HIV infection. It is well known that the response rates to HCV therapy are similar between HCV-monoinfected patients and HIV-HV coinfected ones. The aim of this study was to evaluate the impact of HCV eradication on CD4 + T cell count in a population of HIV-HCV coinfected patients.

Materials and methods: We enrolled patients with HIV-HCV coinfection attending the Infectious Diseases Unit of the A.O.U. Federico II of Naples, from January 2016 to February 2019, treated with ART (AntiRetroviral Therapy) and DAAs (Direct Antiviral Agents). For each patient, we evaluated HIV and HCV viral load and CD4+ T cell count before starting therapy with DAAs, by SVR12 time and by SVR48 time. Fibrosis was evaluated by the mean of Fibroscan®.

Results: Fifty-two patients were enrolled, 40 males. Fibrosis score was F0-F3 in 15 patients and cirrhosis in the remaining 11 (all in Child-Pugh class A). All had been receiving ART, and all were treated with DAAs. Only patient who had not achieved HIV viral suppression for non-compliance also experienced a relapse of HCV infection after the end of DAAs. In all patients, we observed that the CD4+ T cell count at baseline did not show significant variations compared to SVR12 and SVR48 time. We also assessed CD4 count in relation to HIV categories and stage of liver disease, see Table 1. Also, based on the assessments of the subclasses considered, there were no significant changes in the CD4 + T cell count.

Conclusion: Our study shows that HCV viral eradication obtained with DAAs in patients with HIV-HCV coinfection is not associated with significant changes in the CD4 + T cell count, regardless of CDC category and stage of liver disease.

Keywords: CD4+ T cell; DAAs; HCV; HIV; cirrhosis; coinfection; fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Rockstroh JK, Bhagani S, Benhamou Y, et al. EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9(2):82–88. doi:10.1111/j.1468-1293.2007.00535.x - DOI - PubMed
    1. Laiwatthanapaisan R, Sirinawasatien A. Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults. World J Clin Cases. 2021;9(18):4491–4499. doi:10.12998/wjcc.v9.i18.4491 - DOI - PMC - PubMed
    1. Buonomo AR, Scotto R, Zappulo E, et al. Severe Vitamin D deficiency increases mortality among patients with liver cirrhosis regardless of the presence of HCC. In Vivo. 2019;33(1):177–182. doi:10.21873/invivo.11456 - DOI - PMC - PubMed
    1. Ghany M, Morgan TR, MG TR, AASLD-IDSA hepatitis c guidance panel. Hepatitis C Guidance 2019 update: American Association for the Study of Liver Diseases-infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71::686–721. doi:10.1002/hep.31060 - DOI - PMC - PubMed
    1. Di Minno MN, Ambrosino P, Buonomo AR, et al. Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. Intern Emerg Med. 2020;15(2):263–271. doi:10.1007/s11739-019-02163-8 - DOI - PubMed